A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma.

CONCLUSIONS: Even RP and DP groups have the similar survival outcomes and toxicity, raltitrexed/cisplatin get a higher complete response rate. Our study suggests that raltitrexed combined with cisplatin is a safe and effective concurrent chemotherapy regimen and it might be used as an alternative for cisplatin/5-FU and cisplatin/docetaxel in CCRT for EC patients.
PMID: 33419607 [PubMed - as supplied by publisher]

Source: Cancer Radiotherapie - January 5, 2021 Category: Cancer & Oncology Authors: Xia X, Liu Z, Cai B, Di X, Sun X, Ge X Tags: Cancer Radiother Source Type: research